Tavares A, Galvão M
Serviço Imuno.Hemoterapia, Hospital de Santa Maria, Lisboa.
Acta Med Port. 1992 Dec;5(11):587-90.
In the last thirty years, factor VIII concentrates have been the mainstay of hemophilia treatment, first as wet cryoprecipitate and later as dry concentrates commercially available. The evidence of a high risk of blood-born virus transmission by these products provoked the development of new methods for virus inactivation. We report these methods with special attention to their safety, and mention the new perspectives of treatment with recombinant DNA FVIII:C and ultimately by gene insertion therapy.
在过去三十年中，凝血因子 VIII 浓缩物一直是血友病治疗的主要手段，最初是冷沉淀，后来是市售的冻干浓缩物。这些产品存在经血液传播病毒的高风险，这促使人们开发新的病毒灭活方法。我们报告这些方法，并特别关注其安全性，还提及了重组 DNA FVIII:C 治疗以及最终基因插入疗法的新前景。
